Cargando…

Macrophage Inhibitory Cytokine 1 Biomarker Serum Immunoassay in Combination with PSA Is a More Specific Diagnostic Tool for Detection of Prostate Cancer

BACKGROUND: Prostate cancer (PCa) is the most common malignancy among men in the United States. Though highly sensitive, the often-used prostate-specific antigen (PSA) test has low specificity which leads to overdiagnosis and overtreatment of PCa. This paper presents results of a retrospective study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ji, Veltri, Robert W., Yuan, Zhen, Christudass, Christhunesa S., Mandecki, Wlodek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390224/ https://www.ncbi.nlm.nih.gov/pubmed/25853582 http://dx.doi.org/10.1371/journal.pone.0122249

Ejemplares similares

Nuclear Morphometry, Epigenetic Changes, and Clinical Relevance in Prostate Cancer
por: Veltri, Robert W., et al.
Publicado: (2013)

Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA
por: Wang, Ce, et al.
Publicado: (2019)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Mass Spectrometric Immunoassay for the qualitative and quantitative analysis of the cytokine Macrophage Migration Inhibitory Factor (MIF)
por: Sherma, Nisha D, et al.
Publicado: (2014)

Clinicoradiological Spectrum of L-2-Hydroxy Glutaric Aciduria: Typical and Atypical Findings in an Indian Cohort
por: Muthusamy, Karthik, et al.
Publicado: (2019)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Establishment of reference intervals for serum [−2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
por: Wu, Zhi-Yu, et al.
Publicado: (2019)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

Revisiting magnetic resonance imaging pattern of Krabbe disease – Lessons from an Indian cohort
por: Muthusamy, Karthik, et al.
Publicado: (2019)

Falsely Undetectable Prostate-Specific Antigen (PSA) Due to Presence of an Inhibitory Serum Factor: A Case Report and Review of Pertinent Literature
por: Loudas, Nicholas B., et al.
Publicado: (2019)

Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer
por: Mao, Zujie, et al.
Publicado: (2018)

Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers
por: Li, Qing Kay, et al.
Publicado: (2015)

The efficacy of biliary and serum macrophage inhibitory cytokine-1 for diagnosing biliary tract cancer
por: Sugimoto, Mitsuru, et al.
Publicado: (2017)

Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up
por: Bergroth, Robin, et al.
Publicado: (2021)

The role of PSA density in the MRI pathway for prostate cancer diagnostics
por: Cash, Hannes, et al.
Publicado: (2022)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer
por: Lehrer, S, et al.
Publicado: (2002)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Triplexed CEA-NSE-PSA Immunoassay Using Time-Gated Terbium-to-Quantum Dot FRET
por: Bhuckory, Shashi, et al.
Publicado: (2020)

Fasting times in serum PSA assay
por: Xu, Xiang, et al.
Publicado: (2014)

A population study of fasting time and serum prostate-specific antigen (PSA) level
por: Lau, Cheryl K, et al.
Publicado: (2014)

Evaluation of Deoxyribonucleic Acid Damage Using Neutral Comet Assay for High Radiation Doses: A Feasibility Study
por: Raj, Jose Solomon, et al.
Publicado: (2023)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues
por: Nakamura, T, et al.
Publicado: (2003)

Mean Platelet Volume Enhances the Diagnostic Specificity of PSA for Prostate Cancer
por: Song, Wei, et al.
Publicado: (2022)

Correction to: The role of PSA density in the MRI pathway for prostate cancer diagnostics
por: Cash, Hannes, et al.
Publicado: (2023)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
por: Abrate, Alberto, et al.
Publicado: (2014)

Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma
por: Wang, Xiaobing, et al.
Publicado: (2014)

Serum macrophage inhibitory cytokine‐1 as a clinical marker for non–small cell lung cancer
por: Xu, Chunhua, et al.
Publicado: (2021)

Pretreatment Tumor Volume Estimation Based on Total Serum PSA in Patients with Localized Prostate Cancer
por: Kato, Raphael Barroso, et al.
Publicado: (2008)

Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma
por: Guo, Zhaoxin, et al.
Publicado: (2022)

Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial
por: Pye, Hayley, et al.
Publicado: (2021)

Re: Fasting times in serum PSA assay
por: Lau, Cheryl K, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5p8kr28o998ibhkp14023jdrhq